Company Overview
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company focused on advancing two neuroscience programs designed to target a range of neurologic and neuropsychiatric disorders. The company is situated within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - General, which implies a business model centered on the research, development, and potential commercialization of novel therapeutic agents. As of the latest reporting period, the company holds a market capitalization of $43.13M, operates with an annual revenue figure that is not publicly disclosed (N/A), and maintains an employee count listed as N/A. The market cap of $43.13M indicates that MIRA is classified as a small-cap entity, suggesting a position in the market characterized by higher growth potential but typically accompanied by greater volatility and limited operational scale compared to large-cap peers. The absence of disclosed annual revenue and employee data further contextualizes the company's current stage as a pre-clinical entity where traditional revenue streams have not yet been generated, and the organizational workforce size remains unquantified in public filings.
Financial Health
The financial statements for MIRA Pharmaceuticals, Inc. report a Net Income (TTM) of $-28,416M, a Free Cash Flow of $-2,723,576, and an EBITDA figure listed as N/A. The significant negative Net Income of $-28,415,680 relative to the lack of disclosed revenue highlights a cost structure dominated by research and development expenditures typical of pre-clinical-stage biotechnology firms, where operating expenses far exceed current sales. The company's Free Cash Flow stands at $-2,723,576, indicating a consistent burn rate that consumes liquid assets to fund ongoing clinical and pre-clinical activities rather than generating operational cash surplus. This cash outflow suggests the company relies on external capital sources to maintain its research pipeline and operational continuity. All three reported margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a standard metric for pre-clinical-stage companies where no revenue has been recognized to calculate profitability ratios yet. The balance sheet shows Cash on hand of $7.54M while Debt is listed as N/A, creating a scenario where liquid assets exceed liabilities, though the total debt figure is not explicitly quantified. The Current Ratio is reported at 90.53, a metric that requires careful interpretation given the scale of the company and the specific accounting classifications used in its financial reporting. The Return on Equity is -123.3% and the Return on Assets is -74.6%, metrics that reveal management is currently deploying capital to generate value for the future rather than delivering immediate returns to shareholders.
Valuation Assessment
MIRA Pharmaceuticals, Inc. presents a P/E Ratio (TTM) listed as N/A due to negative earnings, while the Forward P/E is -2.51, a figure that reflects the market's pricing of the company based on anticipated future earnings rather than historical performance. The disparity between the unavailable trailing P/E and the negative forward P/E implies that the market is valuing the company entirely on the expectation of future profitability once its neuroscience programs advance beyond the pre-clinical stage. The Price to Book ratio is 5.39, indicating that the market is valuing the company at a significant premium over its book value, a common characteristic for biotechnology firms with intangible assets like patent-pending intellectual property. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (N/A) are unavailable, which limits traditional valuation comparisons and suggests that investors must rely on pipeline potential rather than standard multiples. The stock has traded between a 52-Week High of $2.45 and a 52-Week Low of $0.73, establishing a trading range of $1.72. The Beta value is 1.80, which indicates that the stock is expected to be 80% more volatile than the broader market, reflecting the high-risk nature of pre-clinical-stage pharmaceutical development.
Growth & Income
MIRA Pharmaceuticals, Inc. reports Revenue Growth (YoY) as N/A and Earnings Growth (YoY) as N/A, reflecting its status as a pre-clinical-stage company with no established historical revenue or earnings trajectory to measure against. The absence of growth rates for revenue or earnings precludes a comparison between earnings growth and revenue growth, as both metrics are currently undefined. As a non-dividend payer, the company does not distribute a Dividend Yield (N/A) or maintain a Payout Ratio of 0.0%, which signifies that the company retains all available resources to reinvest into its research and development programs rather than returning cash to shareholders. The overall growth and income profile is defined by the expectation of future commercialization rather than current financial performance, as the company has not yet achieved the revenue milestones necessary to generate income or pay dividends.